Scholarlink

Background/Objectives <p>To assess whether systemic prostacyclin analogue (PCA) therapy in patients with pulmonary arterial hypertension (PAH) is associated with a reduced long-term risk of developing age-related macular degeneration (AMD).</p> Subjects/Methods <p>A retrospective cohort study was conducted using the TriNetX global health research network. Patients aged ≥50 with a diagnosis of PAH were included and stratified by PCA treatment. Propensity score matching (1:1) was applied to balance demographics and comorbidities. Incident diagnoses of non-neovascular AMD (non-nvAMD) and neovascular AMD (nvAMD) were compared across six follow-up intervals (3-15 years) using Kaplan-Meier analysis and Cox proportional hazards models.</p> Results <p>Following matching, 9862 PCA-treated and 9862 untreated PAH patients were analysed. PCA-treated patients showed a consistently lower risk of non-nvAMD across all follow-up periods (hazard ratios [HRs] 0.30-0.37; all <i>p</i> &lt; 0.001). A similar protective trend was observed for nvAMD, with significant associations emerging at longer follow-up (HR = 0.37-0.39 at 10-15 years; <i>p</i> &lt; 0.05). The protective effect was robust and durable over time.</p> Conclusions <p>Systemic administration of prostacyclin analogues is associated with a significant and sustained reduction in AMD risk among patients with PAH. These findings suggest a potential preventive role for PCAs in AMD pathogenesis and merit further investigation in broader populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic prostacyclin analogues in pulmonary hypertension are associated with reduced risk of age-related macular degeneration: a cohort study

  • 期刊论文

  • 发表日期：

    2025年11月4日

查看全文
  • Elad Eilon,
  • Natan Lishinsky-Fischer,
  • Jaime Levy

摘要

Background/Objectives

To assess whether systemic prostacyclin analogue (PCA) therapy in patients with pulmonary arterial hypertension (PAH) is associated with a reduced long-term risk of developing age-related macular degeneration (AMD).

Subjects/Methods

A retrospective cohort study was conducted using the TriNetX global health research network. Patients aged ≥50 with a diagnosis of PAH were included and stratified by PCA treatment. Propensity score matching (1:1) was applied to balance demographics and comorbidities. Incident diagnoses of non-neovascular AMD (non-nvAMD) and neovascular AMD (nvAMD) were compared across six follow-up intervals (3-15 years) using Kaplan-Meier analysis and Cox proportional hazards models.

Results

Following matching, 9862 PCA-treated and 9862 untreated PAH patients were analysed. PCA-treated patients showed a consistently lower risk of non-nvAMD across all follow-up periods (hazard ratios [HRs] 0.30-0.37; all p < 0.001). A similar protective trend was observed for nvAMD, with significant associations emerging at longer follow-up (HR = 0.37-0.39 at 10-15 years; p < 0.05). The protective effect was robust and durable over time.

Conclusions

Systemic administration of prostacyclin analogues is associated with a significant and sustained reduction in AMD risk among patients with PAH. These findings suggest a potential preventive role for PCAs in AMD pathogenesis and merit further investigation in broader populations.